Betsy Althaus

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

Peter Thuss‐Patience, Manish A. Shah, Atsushi Ohtsu et al. · The Lancet Oncology · 2017 · 541 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

Zhimin Shao, Da Pang, Hongjian Yang et al. · JAMA Oncology · 2019 · 193 citations · Full text

Medicine, Oncology, Pharmacology +17

Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

Manfred Welslau, Véronique Dièras, Joohyuk Sohn et al. · Cancer · 2013 · 128 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).

Yoon‐Koo Kang, Manish A. Shah, Atsushi Ohtsu et al. · Journal of Clinical Oncology · 2016 · 84 citations

Medicine, Oncology, Pharmacology +17

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Ian E. Krop, Shanu Modi, Patricia LoRusso et al. · Breast Cancer Research · 2016 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17